Enfortumab vedotin: Phase I data

An open-label, dose-escalation, North American Phase I trial in 28 evaluable patients with metastatic urothelial cancer previously treated

Read the full 187 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE